Detailed introduction to the main manufacturers and corporate background of Apalutamide

Apalutamide (Apalutamide) is an oral androgen receptor inhibitor, mainly used to treat non-metastatic castration-resistant prostate cancer (nmCRPC) and some patients with metastatic prostate cancer. Currently, the main manufacturer of apalutamide is the Japanese pharmaceutical company Toray Pharmaceuticals (a subsidiary of Janssen Pharmaceutical, Johnson & Johnson). Toray Pharmaceuticals has extensive research and development experience in the field of tumors and prostate diseases, and its apalutamide has been approved for marketing in many countries and regions around the world.

Toray Pharmaceuticals is a world-renowned pharmaceutical company. Its parent company Johnson & Johnson (Johnson & Johnson) has strong technical and financial support in the fields of medicine, medical devices and consumer health products. As one of the Group's important innovative drugs in the field of prostate cancer, apalutamide has strict quality control and global regulatory support from research and development, clinical trials to marketing to ensure the safety and effectiveness of the drug.

In addition, the introduction of apalutamide into the domestic market is mainly carried out through Toray Pharmaceutical’s Chinese subsidiaries or partners. The company carries out clinical registration and marketing promotion work domestically to ensure compliance with Chinese drug management regulations and patient medication needs. At the same time, the company also has branches in many domestic cities to facilitate doctors and patients to obtain drug information, medication guidance and clinical support services.

In terms of the global market, apalutamide is not only directly supplied by Toray Pharmaceuticals, but also establishes cooperation channels with distributors and cooperative companies in other regions to ensure the accessibility of the drug in Europe, the United States, Asia and some emerging markets. The strong corporate background and rich research and development experience have made apalutamide widely recognized in clinical applications, and also provided a solid foundation for possible future indication expansion and new dosage form research and development.

Reference materials:https://www.drugs.com/